Bristol-Myers Myeloma Drug Accepted for Priority Review
September 01 2015 - 8:39AM
Dow Jones News
By Angela Chen
Bristol-Myers Squibb Co.'s Empliciti drug, used to treat
multiple myeloma, has been accepted by the U.S. Food and Drug
Administration for priority review.
Empliciti, also known by the chemical name elotuzumab, is
specifically used for multiple myeloma in patients who already have
received one or more therapies. It previously was granted
breakthrough therapy designation, which speeds up the development
and review of drugs for serious illnesses.
The acceptance is supported by promising data from a late-stage,
randomized style that showed the drug was more efficient in
combination with lenalidomide and dexamethasone than lenalidomide
and dexamethasone alone.
Bristol-Myers is co-developing elotuzumab with AbbVie Inc. but
is solely responsible for commercial activities.
Bristol-Myers has gained attention as a leader in developing
drugs that enlist the power of the immune system against cancer. In
another recent study, a combination of the company's immunotherapy
drug Opdivo and skin-cancer drug Yervoy delayed the progression of
melanoma longer than either drug alone, which could support wider
use of both drugs.
Shares, inactive premarket, have fallen 11% in the past three
months through Monday's close.
Write to Angela Chen at angela.chen@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 01, 2015 08:24 ET (12:24 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024